IL6 and inflammatory bowel disease: Preclinical studies in IBD models and mouse colitis models have progressively demonstrated the anti-inflammatory impact of UDCA as it reduces the secretion and accumulation of pro-inflammatory cytokines, including TNF-α, IL-6, IL-12, and IL-1β, along with lowering the immune cell infiltration into the mucosa40–42.